儿童是流感防控的重点人群。相关研究数据显示，我国＜5岁低龄儿童流感疾病负担沉重：0至14岁儿童 每千人流感发病率最高，是15至59岁人群的超过3倍；＜5岁的低龄儿童是流感重症高危群体，易并发肺 炎、急性呼吸窘迫综合征（ARDS）、急性坏死性脑病等，威胁生命安全。 不过，目前针对＜5岁低龄儿童的流感抗病毒治疗选择较为有限，国内仅有神经氨酸酶抑制剂（如奥司 他韦）获批用于<5岁儿童流感抗病毒治疗。尽管该类药物安全性尚可，但在临床应用中依然存在恶 心、呕吐等不良反应，并且需要每天2次连用5天。 此外，近年来国家流感中心耐药监测数据提示耐药率也呈上升趋势，因此在低龄儿童流感抗病毒治疗领 域仍有很大的未满足需求。 在这一背景下，业内呼吁加大对儿童用流感抗病毒药物的研发。近期，首都医科大学附属北京儿童医院 赵成松教授团队牵头完成了玛巴洛沙韦干混悬剂在中国1至＜5岁儿童流感患者中的安全性、临床及病毒 学结果的临床研究，有望为扩大该药物的适应症提供临床证据，这也是首个聚焦中国1至＜5岁流感儿 童，评估玛巴洛沙韦干混悬剂有效性与安全性，将为中国低龄儿童流感抗病毒治疗提供新的选择。 目前针对＜5岁低龄儿童的流感抗病毒治疗选择较为 ...

另据北京儿童医院数据，近期流感阳性检出率明显增加。为充分接收患儿，医院开设不限号门诊、增加 医生出诊单元、启动门诊动态支援等。内科/发热咳嗽门诊开设白班、小夜班、大夜班，24小时接诊。 儿童是流感防控的重点人群。相关研究数据显示，我国<5岁低龄儿童流感疾病负担沉重：0至14岁儿童 每千人流感发病率最高，是15至59岁人群的超过3倍；<5岁的低龄儿童是流感重症高危群体，易并发肺 炎、急性呼吸窘迫综合征（ards）、急性坏死性脑病等，威胁生命安全。<> 不过，目前针对<5岁低龄儿童的流感抗病毒治疗选择较为有限，国内仅有神经氨酸酶抑制剂（如奥司 他韦）获批用于<5岁儿童流感抗病毒治疗。尽管该类药物安全性尚可，但在临床应用中依然存在恶 心、呕吐等不良反应，并且需要每天2次连用5天。<> 第一财经记者今日从上海市儿童医院以及上海交大医学院附属仁济医院、上海交大医学院附属新华医院 等多家医院儿科了解到，近期门急诊接诊量均有较为明显的上升，基本上以流感患儿为主。 以上海交大医学院附属新华医院为例，上周儿科急诊量上升了约20%，两个院区平均每日接诊量达到 1000人左右。 仁济医院儿科医生提醒，今年需特别警惕甲型H3N2毒株 ...

Core Viewpoint - The flu season of 2025 is reported to be more severe than in the past three years, with increased cases of flu-like illnesses (ILI) across both northern and southern regions of China, leading to a shortage of specific flu medications, particularly for children [1][3][11]. Summary by Sections Flu Season Severity - The latest report from the Chinese Center for Disease Control and Prevention indicates that from November 10 to 16, 2025, the ILI percentage in southern provinces was 6.7% and in northern provinces was 7.0%, both higher than the previous week and the same period in 2022, 2023, and 2024 [3][11]. Medication Shortages - Many pharmacies are experiencing shortages of flu medications, particularly the children's version of the antiviral drug "速福达" (Mabalaoshuwei). Traditional antiviral drugs like Oseltamivir are still available but are also in high demand [3][9][11]. - A pharmacy reported that Oseltamivir has been out of stock for over two weeks, with expectations for new supplies to arrive soon, while "速福达" is not expected to be restocked [9][11]. Hospital Preference - Parents prefer hospitals for flu treatment over pharmacies, as they trust clinical doctors more. The original manufacturers of "速福达" and Oseltamivir are ensuring a broad supply to hospitals across the country [10][11]. - Clinical demand for children's flu medications is increasing, with doctors noting that while there are no supply issues for Oseltamivir and Mabalaoshuwei, delivery disruptions can occur due to high demand [11][12]. Drug Efficacy and Usage - Oseltamivir is suitable for children aged 1 year and older, while Mabalaoshuwei is effective for children aged 5 to 12, with the latter being a single-dose oral medication, making it more convenient for parents [11][13]. - The latest guidelines indicate that flu medications are essential for treatment, as common cold medications do not replace antiviral drugs [12][13]. Market Dynamics - The market for children's single-dose flu medications is expected to become more competitive as several domestic pharmaceutical companies are developing similar products, which may challenge the current dominance of "速福达" [16][17]. - Recent approvals for new antiviral drugs targeting children are underway, with a focus on single-dose formulations, which could expand treatment options for pediatric patients [16][17].

Core Insights - Roche Pharmaceuticals China launched the innovative flu drug, Baloxavir Marboxil (速福达), at the 8th China International Import Expo, highlighting its latest clinical data on family transmission prevention and cross-border health protection solutions [1][10] Group 1: Flu Prevention and Treatment Ecosystem - Roche China collaborates with the China Population Welfare Foundation, medical experts, and digital platform partners to create a comprehensive flu prevention and treatment ecosystem covering prevention, detection, treatment, and assurance [4] - The global flu season, from October to March, sees 3 to 5 million severe cases and 290,000 to 650,000 deaths annually, with increased cross-border movement heightening flu transmission risks [6] Group 2: Vaccination and Public Awareness - In China, the flu vaccination rate remains low at 3.84% for the 2022-2023 season, significantly lower than in Europe and the U.S., indicating a need for improved public awareness and vaccination efforts [8] - The China Population Welfare Foundation initiated a global travel protection campaign for the flu season, aiming to enhance public understanding of flu prevention [6] Group 3: Baloxavir Marboxil Efficacy - Clinical data shows that the family treatment regimen of Baloxavir Marboxil can reduce household flu infection rates from 54.45% to 6.93% and shorten symptom duration from 1.14 days to 0.11 days [10] - The drug's single-dose oral administration improves adherence compared to multi-day regimens, addressing challenges in pediatric medication where 43% of children face difficulties [10][11] Group 4: Pediatric Considerations - Children are particularly vulnerable to flu, with longer illness duration and higher viral shedding, necessitating specialized formulations for effective treatment [10] - The Baloxavir Marboxil pediatric formulation is designed for ease of use, allowing precise dosing based on weight, thus enhancing the medication experience for children [11] Group 5: Commitment to Public Health - Roche emphasizes its commitment to public health and the "Healthy China 2030" initiative, aiming to enhance flu prevention and treatment through scientific advancements and collaboration with various sectors [11]